Drug Trial Radar · NCT01109173
Confirmatory Study Nepafenac 0.3%
Last checked: Nov 20, 2026Latest source record: Nov 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,120
Actual
Start
Jun 2010
Primary completion
May 2011
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
Conditions
- Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.3%Drug
Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
Nepafenac Ophthalmic Suspension, 0.1%Drug
Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
Nepafenac Ophthalmic Suspension 0.3% VehicleOther
Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
NEVANAC VehicleOther
Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Cured at Day 14Time frame: Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.